Poly Medicure Ltd. (POLYMED) — Tipsheet

Poly Medicure's Q4 profit drops 29% as acquisition costs bite

Tipsheet Editorial — Mon, 25 May 2026 19:58:49 GMT

Consolidated net profit fell 29% in Q4, with standalone down 7%. The results confirm softer trends already flagged in an earlier concall.

What’s new

Poly Medicure's Q4 consolidated net profit fell ~29% YoY, partly due to acquisition-related costs.
Standalone Q4 net profit declined ~7% YoY.
Board approved a dividend and routine auditor reappointments alongside the results.

Why it matters

The results are not a surprise. The market already knew about the revenue baseline cut for PendraCare and the reduced renal growth target from a prior concall. This filing simply confirms the financial impact of those known headwinds, offering no new model revision triggers.

What we’re watching

The pace at which acquisition-related costs normalize in coming quarters.
Any update on the execution against the revised renal growth target.
The dividend payout ratio relative to the lower profit base.

The full read

Poly Medicure's Q4 consolidated net profit fell 29% year-on-year, a decline partly driven by acquisition-related costs. Standalone profit dropped 7%. The numbers land without shock because the company had already told investors in a concall that its PendraCare revenue baseline was cut and its renal growth target was reduced. This filing confirms the profit impact of those known headwinds. For investors, the incremental value is in seeing the cost profile play out in audited accounts. The dividend recommendation and auditor reappointments are routine. The open question is whether acquisition costs fade in the next two quarters, or stick around.

Primary source: BSE · NSE

Poly Medicure walks back PendraCare revenue, renal growth targets

Tipsheet Editorial — Mon, 25 May 2026 18:16:19 GMT

The post-results call corrected a key metric downward and cut a growth forecast, while acquisitions weighed on margins.

What’s new

PendraCare's annualized CY25 revenue corrected to EUR8mn from the EUR10mn cited in February.
Renal segment growth target cut to 'over 20%' from 30-35% due to Chinese dumping.
Acquisitions (PendraCare, CTF) posted a negative EBITDA impact of ₹2.6 crore in Q4 FY26.

Why it matters

The PendraCare revision is a direct walk-back of a number given to the market just three months ago. Combined with a 200-300 bps gross margin erosion forecast for FY27, the guidance for 25-27% standalone EBITDA margin looks stretched.

What we’re watching

Whether Chinese dumping in renal devices intensifies or stabilizes.
Poly Medicure's ability to hold the 25-27% EBITDA margin target.
Progress toward integrating PendraCare and CTF at the guided 12-14% margin.

The full read

Poly Medicure's post-results concall started with a correction. PendraCare's annualized CY25 revenue is EUR8mn, not the EUR10mn given in February. The renal growth target was cut from 30-35% to 'over 20%', with Chinese dumping blamed. Acquisitions dragged Q4 EBITDA by ₹2.6 crore and run at 12-14% margins, short of the earlier 15% guide. For FY27, revenue is guided at ₹2,300-2,400 crore and standalone EBITDA margin at 25-27%, but gross margin is set to erode 200-300 bps to about 66% on raw material and wage costs. The revisions strip credibility from earlier guidance. The FY27 margin target is the real test now.

Primary source: BSE · NSE

Poly Medicure's Q4 profit drops 7% standalone, 29% consolidated on acquisition costs

Tipsheet Editorial — Mon, 25 May 2026 16:42:17 GMT

Standalone net profit slipped to ₹8,062 lacs while consolidated profit took a 29% hit from deal-related expenses. Full-year standalone profit rose just 1.4%.

What’s new

Poly Medicure's standalone Q4 net profit fell ~7% year-on-year to ₹8,062 lacs.
Consolidated Q4 profit dropped ~29% due to costs from recent acquisitions.
Full-year standalone profit grew just ~1.4% to ₹33,598 lacs.

Why it matters

The standalone results show a business with mild top-line pressure. The consolidated figure, however, is where the acquisition costs hit, dragging the final quarter's performance. A ~1.4% full-year profit increase against a ~29% Q4 consolidated decline isolates the deal impact to the final period.

What we’re watching

Whether acquisition costs persist as a drag on consolidated margins in coming quarters.
If the standalone business can return to growth after the weak Q4.
Management commentary on when deal-related expenses normalize.

The full read

Poly Medicure's standalone Q4 net profit slipped ~7% to ₹8,062 lacs, but the real story is in the consolidated numbers. Those fell ~29% because of costs tied to recent acquisitions. For the full year, standalone profit managed a ~1.4% increase to ₹33,598 lacs, but the final quarter's weakness capped the growth. The dividend stays at ₹3.5 per share. The filing is routine; there are no major surprises or new guidance. The open question is how long those deal costs will weigh on the consolidated books before any acquisition-related expenses normalize.

Primary source: BSE · NSE

Poly Medicure profit slips in Q4, hit by acquisition costs

Tipsheet Editorial — Mon, 25 May 2026 15:23:30 GMT

Standalone net profit fell 7% even as revenue grew. On a consolidated basis, profit dropped 29% as acquisition-related expenses weighed.

What’s new

Q4 standalone net profit fell ~7% YoY to ₹8,062 lacs despite 5% revenue growth.
Consolidated Q4 net profit dropped ~29% to ₹6,504 lacs, partly due to acquisition costs.
Full-year standalone net profit grew just ~1.4% to ₹33,598 lacs.

Why it matters

The consolidated profit drop is twice the standalone decline, a clear sign that acquisition costs are eating into the group's earnings. Standalone margin pressure suggests the core business itself isn't fully immune either.

What we’re watching

Whether acquisition-related costs are a one-time event or a recurring drag.
Management commentary on integration progress and cost rationalisation.
Trend in standalone margins as revenue growth slows.

The full read

Poly Medicure's Q4 results show a business growing its top line but struggling to translate that into bottom-line gains. Standalone revenue of ₹44,301 lacs rose ~5% YoY, yet standalone net profit slipped ~7% to ₹8,062 lacs. The steeper consolidated profit drop of ~29% to ₹6,504 lacs points to acquisition-related costs weighing on the group. For the full year, standalone net profit of ₹33,598 lacs managed just ~1.4% growth. Hardly moving. The board's ₹3.5 per share dividend is a routine shareholder return. The real story is the margin compression, particularly in the consolidated numbers, and what it means for the company's acquisition strategy. There is no new guidance or commentary to explain the cost pressures.

Primary source: BSE · NSE